Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression.

First study of ensovibep in patients with symptomatic COVID-19 disease Designed to evaluate dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep Ensovibep is additionally planned to be tested in two global, placebo controlled, double blinded trials: A Phase 2-3 trial in an

Zurich-Schlieren, Switzerland, March 26, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today   published the invitation to the Annual General Meeting 2021.

Pharmaceutical industry expert with extensive knowledge of R&D and commercialization Zurich-Schlieren, Switzerland, March 25, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics,

Zurich-Schlieren, Switzerland, March 22, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it plans to conduct a registered public offering of its ordinary

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3 Clinical trial includes an interim analysis after 300 patients

Acknowledged innovation leader with deep scientific and business expertise in immunotherapy, oncology and infectious diseases Zurich-Schlieren, Switzerland, March 11, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein

Zurich-Schlieren, Switzerland, March 10, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today   announced the upcoming presentation of four posters with data supporting three of

Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 Zurich-Schlieren, Switzerland, March

Zurich-Schlieren, Switzerland, February 26, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published its audited Financial Results for 2020 and the company’s 2020 Annual Report.